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Abstract
Background. Longitudinal measurement of glioma burden with MRI is the basis for treatment response assessment. In 
this study, we developed a deep learning algorithm that automatically segments abnormal fluid attenuated inversion re-
covery (FLAIR) hyperintensity and contrast-enhancing tumor, quantitating tumor volumes as well as the product of max-
imum bidimensional diameters according to the Response Assessment in Neuro-Oncology (RANO) criteria (AutoRANO).
Methods. Two cohorts of patients were used for this study. One consisted of 843 preoperative MRIs from 843 
patients with low- or high-grade gliomas from 4 institutions and the second consisted of 713 longitudinal post-
operative MRI visits from 54 patients with newly diagnosed glioblastomas (each with 2 pretreatment “baseline” 
MRIs) from 1 institution.
Results. The automatically generated FLAIR hyperintensity volume, contrast-enhancing tumor volume, and 
AutoRANO were highly repeatable for the double-baseline visits, with an intraclass correlation coefficient (ICC) of 
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0.986, 0.991, and 0.977, respectively, on the cohort of postoperative GBM patients. Furthermore, there was 
high agreement between manually and automatically measured tumor volumes, with ICC values of 0.915, 
0.924, and 0.965 for preoperative FLAIR hyperintensity, postoperative FLAIR hyperintensity, and postopera-
tive contrast-enhancing tumor volumes, respectively. Lastly, the ICCs for comparing manually and automat-
ically derived longitudinal changes in tumor burden were 0.917, 0.966, and 0.850 for FLAIR hyperintensity 
volume, contrast-enhancing tumor volume, and RANO measures, respectively.
Conclusions. Our automated algorithm demonstrates potential utility for evaluating tumor burden in com-
plex posttreatment settings, although further validation in multicenter clinical trials will be needed prior to 
widespread implementation.
Key Points
1.  An algorithm that automatically segments postoperative glioblastoma was 
developed.
2.  The calculation of the product of maximum bidimensional diameters was 
automated.
3.  Automated measures are in agreement with human experts for changes in tumor 
burden.
Gliomas are primary central nervous system tumors with 
variable natural histories and prognoses depending on their 
histologic and molecular characteristics.1 The current gold 
standard to determine treatment response and assess tumor 
progression in clinical trials is the Response Assessment in 
Neuro-Oncology (RANO) criteria.2 For high-grade gliomas, 
including glioblastomas (GBMs), radiographic response as-
sessment is based on (i) measurement of the 2D product of 
maximum bidimensional diameters of contrast-enhancing 
tumor and (ii) qualitative evaluation of T2/fluid-attenuated 
inversion recovery (FLAIR) abnormal hyperintense re-
gions.2,3 However, manual delineation of tumor boundaries 
can be difficult due to the infiltrative nature of gliomas and 
presence of heterogeneous contrast enhancement, which 
is particularly common during anti-angiogenic treatment. 
As a result, there can be substantial interrater variability in 
2D measurements for both contrast-enhancing and FLAIR 
hyperintense tumors.4–6 Furthermore, variability in seg-
mentation can introduce substantial variability in calcu-
lated mean values of multi-parametric magnetic resonance 
(MR) parameters, such as the volume transfer constant.7 
Consequently, there is great interest in developing repro-
ducible automated methods for segmentation and calcula-
tion of the product of maximum bidimensional diameters.
Although 2D linear measurements currently represent 
the gold standard for response assessment, volumetric 
measurements may capture tumor burden more accu-
rately, particularly because gliomas are often irregularly 
shaped. However, volumetric response assessment has 
not been adopted for routine use due to the laborious 
efforts needed to perform tumor segmentation using ex-
isting tools and a lack of large-scale studies validating its 
benefit over simpler 2D approaches. A  recent consensus 
paper on brain tumor imaging in clinical trials noted vol-
umetric analysis as an improvement to current protocols.8 
An automated segmentation tool could help facilitate 
the use of tumor volume as a response endpoint in clin-
ical trials and allow integration into the clinical workflow. 
Rapid and reproducible tumor segmentation is also an es-
sential step toward voxel-based quantitative assessment 
of single as well as multi-parametric imaging biomarkers 
of tumor response to treatment.9–13
Importance of the Study
Longitudinal measurement of glioma burden with MRI is 
the basis for treatment response assessment. Experts 
in neuro-oncology routinely make manual estimates 
of tumor size based on the product of bidimensional 
diameters of enhancing tumor. However, this proce-
dure is time-consuming and subject to interobserver 
variability. In this study, we developed an algorithm 
that automatically segments FLAIR hyperintensity and 
contrast-enhancing tumor, quantitating tumor volumes 
as well as the product of maximum bidimensional 
diameters according to the RANO criteria (AutoRANO). 
We show that automated volume and RANO 
measurements are highly repeatable and are in agree-
ment with human experts in terms of change in tumor 
burden during the course of treatment. This tool may 
be helpful in clinical trials and clinical practice for 
expediting measurement of tumor burden in the eval-
uation of treatment response, decreasing the time 
expended by clinicians for manual tumor segmentation, 
and decreasing interobserver variability.
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With the advent of more powerful graphics processing 
units, deep learning has become the method of choice for 
automatic segmentation of medical images.14,15 At the core 
of deep learning is the convolutional neural network; a ma-
chine learning technique that can be trained on raw image 
data to predict clinical outputs of interest. Existing deep 
learning methods have not been developed for the post-
operative setting, where the surgical cavity and brain dis-
tortion make it difficult to reliably outline the boundaries of 
the tumor.14,16
There are 2 key challenges to automatic tumor segmen-
tation. The first challenge is variability in brain extraction, 
an image preprocessing technique that separates the 
brain from skull and is essential for many neuroimaging 
applications.17 Removing the skull from the image prevents 
automatic segmentation algorithms from falsely labeling 
non-brain regions as tumor and enables consistent inten-
sity normalization across all patients. Many automated 
methods exist for brain extraction, but their generaliza-
bility is limited.18–22 Without manual correction, poor brain 
extraction can introduce errors into downstream automatic 
segmentation.23 This is particularly important in the post-
operative setting due to the widely heterogeneous and var-
iable appearance of surgical cavity, calvarium, and scalp. 
The second challenge is generalizability: MR intensity 
values vary substantially depending on the MR scanner 
properties (including manufacturer, scanner type, and field 
strength) and acquisition parameters (including echo time, 
repetition time, and contrast injection dose/timing) and 
can result in substantial differences in tumor appearance.8 
Consequently, algorithms trained on limited datasets may 
not apply well to data acquired from different institutions, 
acquisition protocols, and patient populations.
In this study, we developed a fully automated pipeline 
for brain extraction and tumor segmentation that can be 
used to reliably generate abnormal FLAIR hyperintensity 
and contrast-enhancing tumor volumes as well as 2D 
bidimensional diameters according to the RANO criteria. 
We then validated the performance of the algorithm in 
both a multi-institutional preoperative patient cohort and 
a longitudinal postoperative patient cohort from a single 
institution by comparing automated measurements to 
manual measurements derived from experts.
Materials and Methods
Preoperative Patient Cohort
The study was conducted following approval by the Hospital 
of the University of Pennsylvania (HUP) and the Partners 
Institutional Review Boards. Glioma patients at HUP, The 
Cancer Imaging Archive (TCIA), Massachusetts General 
Hospital (MGH), and Brigham and Women’s Hospital (BWH) 
were retrospectively identified. The imaging study dates 
for HUP, MGH, and BWH ranged from 1998 to 2016. For the 
TCIA cohort, we identified glioma patients with preopera-
tive MRI data from The Cancer Genome Atlas and IvyGap.24 
All patients met the following criteria: (i) histopathologically 
confirmed grades II–IV glioma according to World Health 
Organization criteria (2007 or 2016 criteria, depending on 
whether the case occurred before or after 2016) and (ii) avail-
able preoperative MRI consisting of T2-weighted FLAIR and 
post-contrast T1-weighted (T1 post-contrast) images. Patients 
were excluded if glioma was not histopathologically con-
firmed, either FLAIR or T1 post-contrast imaging was unavail-
able, or there was excessive motion artifact on imaging. The 
acquisition settings of the imaging for the preoperative pa-
tient cohort are shown in Supplementary Figures 1–2. For the 
preoperative cases, both 2D and 3D T1-weighted images were 
used, depending on which were available. Three-dimensional 
T1-weighted imaging was available for 29% of the patients in 
the preoperative patient cohort.
Postoperative Patient Cohort
MRI data were acquired from 2 clinical trials at MGH that 
enrolled patients with newly diagnosed glioblastoma re-
ceiving standard chemoradiation (NCT00756106) or 
standard chemoradiation with cediranib (NCT00662506). 
There were 54 total patients. The Dana-Farber/Harvard 
Cancer Center institutional review board approved these 
studies. Inclusion criteria for both trials were age >18 years, 
post-surgical residual contrast-enhancing tumor size of 
≥1 cm in one dimension, histologically confirmed diagnosis 
of glioblastoma, and eligibility for standard therapy after sur-
gery. For NCT00756106, MRI was performed at the following 
timepoints: within 1 week of starting chemoradiation therapy 
(baseline visit 1), 1  day before starting chemoradiation 
therapy (baseline visit 2), weekly during chemoradiation, 
and monthly before each cycle of adjuvant temozolomide 
until disease progression or at least until completion of 
6 cycles of adjuvant temozolomide (whichever occurred 
first).25 MRI timepoints for NCT00662506 were previously 
described by Batchelor et al.26 MRI was performed at 3.0 T 
(TIM Trio, Siemens Healthcare) and included FLAIR images 
(repetition time [TR] = 10 000 ms, echo time [TE] = 70 ms, 
5 mm slice thickness, 1 mm interslice gap, 0.43 mm in-plane 
resolution) and both pre- and post-contrast T1-weighted 
images (TR = 600 ms, TE = 12 ms, 5 mm slice thickness, 1 mm 
interslice gap, 0.43 mm in-plane resolution).
Expert Brain Extraction, Tumor Segmentation, 
and RANO Measurements
Brain extraction was performed in 42 randomly selected 
patients from the preoperative and postoperative patient 
cohort by one rater (R.Y.H., neuroradiologist, 9 years expe-
rience). Manual tumor segmentations were performed on 
the FLAIR hyperintense areas in the preoperative patient 
cohort (Q.S., neuroradiologist, 5 years experience; R.Y.H.; 
A.B., neurosurgery resident, 5 years experience) and the 
FLAIR hyperintense as well as contrast-enhancing tumor 
areas in the postoperative patient cohort (E.R.G., neuro-
oncologist, 12 years experience; M.C.P., neuroradiologist, 
11 years experience), with segmentation for each patient 
visit performed by a single expert evaluating both the pre- 
and post-contrast MRIs to exclude postoperative blood 
products. Manual RANO bidirectional measurements as 
well as assessment for FLAIR progression were performed 
by 2 raters (E.R.G.  and K.I.L., neuro-oncologist, 7  years 
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experience) for both baseline visits, the visit with the 
lowest manual contrast-enhancing tumor volume, and the 
last patient visit from the postoperative patient cohort.27
Deep Learning–Based Brain Extraction
The 42 patients for whom expert brain mask extraction was 
performed were divided into training (n = 30) and testing (n 
= 12) sets. The neural network was trained on the training set. 
As a point of reference, we compared brain extraction using 
our deep learning algorithm with that of other commonly 
used automatic brain extraction methods (Hybrid Watershed 
Algorithm, Robust Learning-Based Brain Extraction, Brain 
Extraction Tool, 3dSkullStrip, and Brain Surface Extractor).17–22 
All methods were applied to the T1 post-contrast images 
using default parameters, except for Robust Learning-Based 
Brain Extraction, which has no tunable parameters.
Deep Learning–Based Abnormal FLAIR 
Hyperintensity and Contrast-Enhancing Tumor 
Segmentation
The HUP,  TCIA, and MGH patient preoperative cohorts 
were randomly divided into training and testing sets in 
a 4:1 ratio. The BWH patient cohort was used as an inde-
pendent testing set. A  single neural network model was 
trained for FLAIR hyperintensity segmentation in the pre-
operative patient cohort using only the training set. Once 
the model was trained, performance was assessed on the 
testing and independent testing sets.
The patients from the single institutional postoperative pa-
tient cohort were randomly divided into training and testing 
sets in a 4:1 ratio. Data were split on a patient level such that 
all visits for a patient were entirely in either the training or 
test set (Supplementary Fig. 3). Two neural network models 
were trained for the postoperative patient cohort: FLAIR 
hyperintensity segmentation and contrast-enhancing tumor 
segmentation. Only the training set was used during training 
of the model. Once trained, the performance of the model 
was assessed on the separate testing set.
Neural Network Architecture and Postprocessing
We utilized the 3D U-Net architecture, a neural network 
designed for fast and precise segmentation, for both brain ex-
traction and tumor segmentation (Supplementary Fig. 4B).28,29 
Similar to the original 2D U-Net, our architecture consists 
of a downsampling and an upsampling arm with residual 
connections between the two that concatenate feature maps 
at different spatial scales. The networks were designed to re-
ceive input patches from multiple channels: (i) FLAIR and T1 
post-contrast images for brain extraction, (ii) FLAIR and T1 
post-contrast images for FLAIR hyperintensity segmentation 
in the preoperative patient cohort, (iii) FLAIR, T1 pre-contrast, 
and T1 post-contrast images for FLAIR tumor segmentation 
in the postoperative patient cohort, and (iv) FLAIR, T1 pre-
contrast, T1 post-contrast, and FLAIR hyperintensity region for 
contrast-enhancing tumor segmentation in the postoperative 
patient cohort. Rectified linear unit (ReLU) activation was used 
in all layers, with the exception of the final sigmoid output. 
Batch normalization was applied after each convolutional 
layer for regularization. We used Nestorov adaptive moment 
estimation to train the 3D U-Nets with an initial learning rate 
10−5, minimizing a soft Dice loss function:
  
D (p,g) =
2
∑
i gipi∑
i (gi + pi) + α  (1)
where D is Dice, p is the probability output of the neural 
network, g is the ground truth, and α is a constant. Our 
networks were implemented in DeepNeuro with Keras/
Tensorflow backend.30 Each U-Net was trained on a NVIDIA 
Tesla P100 graphics processing unit. During training, 20% 
of the training set was withheld as a validation set. For 
brain extraction, 50 patches (64 × 64 × 8) were extracted, 
randomly, for each patient in the training set and 10 
patches were extracted for each patient in the validation 
set. For tumor segmentation, 20 patches (64 × 64 × 8) were 
extracted from normal brain and FLAIR hyperintense re-
gions in a 1:1 ratio for each patient in the training set, and 
4 patches were extracted for each patient in the validation 
set. Before patches were used to train the network, they 
were augmented by means of sagittal flips. Augmentation 
increases the size of the training set while also preventing 
overfitting.13 The network was trained through all extracted 
patches until the validation loss did not improve for 10 
consecutive iterations. Once the network was trained, in-
ference was performed by gridding the MR images into 
patches at 8 different offsets from the uppermost corner 
of the image. The model then predicted probability maps 
for each of these patches, and voxels with predictions 
from multiple overlapping patches had their probabilities 
averaged. For prediction of the contrast-enhancing tumor 
regions, the output probability map from the FLAIR 
hyperintensity segmentation neural network was used as 
input instead of the manually derived FLAIR hyperintensity 
region.
AutoRANO Algorithm
We developed an AutoRANO algorithm to automatically de-
rive RANO measurements from our automatic deep learning–
based contrast-enhancing tumor segmentations as described 
above. The algorithm searches for the axial slice with the largest 
tumor area and determines if the lesion is measurable. A meas-
urable lesion was defined as a minimum length of both perpen-
dicular measurements ≥12 mm (based on a threshold of 10 mm 
if slice thickness + gap ≤ 5 mm or a threshold of 2 × [slice thick-
ness + gap] if slice thickness + gap > 5 mm).31 If the lesion was 
measurable, the product of maximum bidimensional diameters 
was automatically derived by first exhaustively searching for 
the longest diameter and then the corresponding longest per-
pendicular diameter. The angle between the longest diam-
eter and the perpendicular diameter was restricted to 85–95°. 
If there was more than one measurable lesion on the same 
scan, the products of maximal bidimensional diameters were 
summed (for up to 5 measurable lesions).31 The AutoRANO al-
gorithm was applied to the automatically segmented contrast-
enhancing tumor regions (Fig. 1C).
Statistical Analysis
Neural network segmentation was compared with expert 
segmentation by means of the Sørensen–Dice coefficient, 
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sensitivity, and specificity, and evaluated statistically using 
Dunnet’s test (significance level P  <  0.05). Comparison of 
volume and RANO measurements were assessed via ei-
ther Spearman’s rank correlation coefficient (ρ [Greek letter 
rho]) or intraclass correlation coefficient (ICC) (significance 
level P < 0.05). Further details of ICC calculation are in the 
Supplementary Material. For the postoperative patient co-
hort, the nadir was defined as the minimum volume or 
minimum 2D linear measurements at any timepoint from 
baseline to last visit. For longitudinal comparison of volume 
and RANO measurements, the last patient visit was assessed 
relative to the nadir (delta measure  =  volume or RANO 
measure of the last patient visit—volume or RANO measure 
of the nadir).
Code and Data Availability
The codes for preprocessing, U-Net architecture, and 
postprocessing are publicly available at: https://github.
com/QTIM-Lab/DeepNeuro.  Accessed June 23, 2019.30
Results
Patient Cohorts
Our final preoperative patient cohort included 239 patients 
from HUP, 293 patients from TCIA, 154 patients from MGH, 
and 157 patients from BWH. Our final postoperative patient 
cohort consisted of 713 visits from 54 patients from MGH. 
Twenty-one patient visits were excluded due to missing 
MRI sequences or excessive motion artifact. Patient char-
acteristics are shown in Supplementary Table 1.
Deep Learning–Based Brain Extraction
We compared brain extraction using our deep learning algo-
rithm, based on the 3D U-Net architecture,29 with that of both 
human expert and commonly used brain extraction software 
packages. The mean Dice score between our algorithm and 
manual expert brain extraction was 0.935 (95% CI: 0.918–0.948) in 
the testing set (Supplementary Table 2, Supplementary Fig. 5A). 
Compared with other commonly used brain extraction 
techniques (Supplementary Table 2), our algorithm had the 
highest Dice score and specificity for the testing set. When the 
U-Net was applied to all 843 patients in the preoperative patient 
cohort, the mean fraction of FLAIR hyperintensity retained in 
the extracted brain image (defined as tumor volume remaining 
in the brain-extracted image divided by total tumor volume) 
was 0.987 (95% CI: 0.984–0.990; Supplementary Fig. 5B). 
When applied to the 713 patient visits in the postoperative 
patient cohort, the mean fraction of FLAIR hyperintensity and 
contrast-enhancing tumor retained in the extracted brain 
image was 0.996 (95% CI: 0.994–0.997; Supplementary Fig. 5C) 
and 0.982 (95% CI: 0.977–0.987), respectively.
Deep Learning–Based FLAIR Hyperintensity and 
Contrast-Enhancing Tumor Volume Segmentation
The average time for brain extraction, FLAIR hyperintensity, 
and contrast-enhancing tumor segmentation was 19 seconds 
using our trained algorithms. For the testing set of the pre-
operative patient cohort, the mean Dice score for FLAIR 
hyperintensity segmentation was 0.796 (95% CI: 0.753–0.803) 
(Supplementary Table 3). For the independent testing set, the 
mean Dice score for automatic FLAIR hyperintensity segmen-
tation compared with expert human segmentation was 0.819 
  
ManualA
B
CAutomatic
Manual Automatic
Fig. 1 Example of manual vs automatic FLAIR hyperintensity segmentation (A) and enhancing-tumor segmentation (B) for the testing set in the 
postoperative patient cohort. (C) Examples of AutoRANO applied to automatic enhancing segmentations on the postoperative patient cohort.
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(95% CI: 0.793–0.842). Examples of FLAIR hyperintensity 
segmentations for the independent testing set of the preop-
erative patient cohort are shown in Supplementary Fig. 7. For 
the testing set of the postoperative patient cohort, the mean 
Dice score for automatic FLAIR hyperintensity segmentation 
compared with manual segmentation was 0.701 (95% CI: 
0.670–0.731). The mean Dice score for automatic segmenta-
tion compared with manual contrast-enhancing tumor seg-
mentation was 0.696 (95% CI: 0.660–0.728).
Examples of FLAIR hyperintensity and contrast-
enhancing tumor segmentations for the testing set of 
the postoperative patient cohort are shown in Fig. 1A, B. 
Examples of longitudinal tracking of FLAIR hyperintensity 
and contrast-enhancing tumor volumes for 2 patients in 
the testing set are shown in Supplementary Fig. 9. The ICC 
for calculated FLAIR hyperintensity volumes between auto-
matic and manual segmentation was 0.915 (P < 0.001) in the 
preoperative and 0.924 (P < 0.001) in the postoperative pa-
tient cohorts. The ICC for contrast-enhancing tumor volume 
in the postoperative patient cohort was 0.965 (P < 0.001; Fig. 
3). In the rare cases when the algorithm was off, the reason 
was due to similarity in signal intensity between normal 
brain and tumor—a similar challenge for human readers 
(Supplementary Figures 7D and 8).
Repeatability of Volume and RANO 
Measurements in the Postoperative 
Patient Cohort
Repeatability of manual and automatic measurements was 
assessed by comparing measurements from the 2 baseline 
visits for each patient. Comparing baseline visits 1 and 2 for 
FLAIR hyperintensity volume, the ICC was 0.983 (P < 0.001) 
for manual volume measurement and 0.986 (P < 0.001) for 
automatic volume measurement. For contrast-enhancing 
tumor volume, the ICC was 0.964 (P  < 0.001) for manual 
volume measurement and 0.991 (P < 0.001) for automatic 
volume measurement.
Comparing baseline visits 1 and 2 for RANO 
measurements, the ICC was 0.984 (P < 0.001) for manual 
RANO and 0.977 (P < 0.001; Fig. 2) for AutoRANO. Notably, 
there were 5 patients assessed by one rater who had meas-
urable lesions on one but not the other baseline visit. 
Similarly, there were 3 patients assessed by the other rater 
who had measurable lesions on one but not the other 
baseline visit. By comparison, when using the AutoRANO 
algorithm, no patients had a discrepancy in the presence/
absence of measurable lesions between the 2 baseline 
visits.
Interrater Agreement for Manual RANO and 
Agreement Between Manual RANO and 
AutoRANO
In assessing interrater agreement, the ICC for manual 
RANO measurements between the 2 expert raters was 
0.704 (P < 0.001). In assessing rater–algorithm agreement, 
the ICC was 0.768 (P < 0.001) between AutoRANO and Rater 
4 and 0.501 (P  <  0.001; Fig. 4) between AutoRANO and 
Rater 6.
Automatic Treatment Response Assessment
Comparisons between nadir and the last patient visit were 
made (delta measure  =  last patient visit measure—nadir 
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measure). In assessing rater–algorithm agreement for 
the delta measures, the ICC between automatic and 
manual delta measurements were 0.917 (P < 0.001), 0.966 
(P < 0.001), and 0.850 (P < 0.001) for FLAIR hyperintensity 
volume, contrast-enhancing tumor volume, and RANO 
measures, respectively (Fig. 5).
Correlation Between RANO Measures and 
Manual Volume
Spearman’s ρ coefficient between manual RANO 
measures and manual enhancing-tumor volume was 
0.787 (P  <  0.001). Spearman’s ρ coefficient between 
AutoRANO measures and manual enhancing-tumor 
volume was 0.940 (P < 0.001; Fig. 6). Spearman’s ρ coef-
ficient between delta manual RANO measures and delta 
manual enhancing-tumor volume was 0.744 (P  < 0.001). 
Spearman’s ρ coefficient between delta AutoRANO meas-
ures and delta manual enhancing-tumor volume was 
0.832 (P < 0.001, Supplementary Fig. 11).
Discussion
In this study, we demonstrate the utility of a fully auto-
mated, deep learning–based pipeline for calculation of 
tumor volumes and RANO measurements. A  key image 
preprocessing step is brain extraction, which removes 
non-brain tissue—a significant source of error for down-
stream tumor segmentation. We trained a network on ex-
pert brain-extracted images from patients who underwent 
heterogeneous imaging acquisition protocols and dem-
onstrate its superiority compared with other commonly 
used skull-stripping methods. After brain extraction, a deep 
learning framework was applied for FLAIR hyperintensity 
and contrast-enhancing tumor volume segmentation. 
Even with the varied acquisition protocols, our automatic 
pipeline proved to be robust for segmentation in the ma-
jority of patients in our multi-institutional dataset. We fur-
ther developed an algorithm for automatic calculation of 
RANO measurements from contrast-enhancing tumor 
segmentations. In addition to the preoperative setting, our 
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algorithm demonstrated good performance in postopera-
tive MRIs, which are particularly challenging given the fre-
quent presence of surgical cavities and brain distortion. 
Furthermore, the algorithm was successfully applied in a 
longitudinal patient cohort including patients who had been 
treated with cediranib, which blunts the contrast enhance-
ment, yielding ill-defined contrast enhancement margins 
that are difficult to contour. It is in these cases, particularly, 
that standardized segmentation is likely to be most helpful.
Based on the double baseline MRIs, both manually and au-
tomatically derived FLAIR hyperintensity volume, contrast-
enhancing tumor volume, and RANO measurements were 
highly repeatable, showing intrarater consistency. However, 
there were differences in interrater consistency. The RANO 
measurements from the AutoRANO algorithm were, on av-
erage, larger than those of the 2 human raters. This is likely 
due to the fact that our AutoRANO algorithm performs an ex-
haustive search of the longest perpendicular diameters while 
a human performs this estimation by eye, which is a less ac-
curate method. This inaccuracy is further evidenced by the 
fact that the average RANO measurements differed between 
the 2 raters. In fact, consistent with prior reports on the var-
iability in 2D measurements,4 it is not surprising that there 
was substantial variability between RANO measurements 
between our raters. In contrast, we found high agreement 
between manual raters and automatic volume for both 
contrast-enhancing tumor and FLAIR hyperintensity. This 
suggests that volume measurements allow for greater con-
sistency across raters than RANO measurements.
There was high agreement between manual and auto-
matic measures with regard to changes in tumor burden 
(both contrast-enhancing and FLAIR hyperintensity) during 
the course of longitudinal therapy. However, there was 
better agreement between manual raters and automated 
measurements for contrast-enhancing tumor volume 
compared with RANO measures. Thus, automated volume 
measurements were superior to AutoRANO measurements 
due to higher concordance with manual methods.
Interestingly, AutoRANO correlated better with manual 
contrast-enhancing tumor volume than the manual RANO 
measurements. Delta AutoRANO (the difference in the 
bidimensional measurements between the last visit and 
the nadir scan) also correlated better with delta manual 
contrast-enhancing tumor volume than delta manual 
RANO measurements. This suggests that AutoRANO may 
be a more accurate measure of tumor burden than manual 
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RANO measurement in addition to the advantage of being 
fully automated.
One point to note is that the ICC values for manual 
versus automatic volumes were higher than the Dice 
scores for manual versus automatic segmentation. This 
is because Dice is a measure of the spatial overlap be-
tween the ground truth and segmentations, while the 
ICC compares volumes without considering spatial lo-
cation. Both metrics provide useful but complementary 
information. Dice as a measure is more sensitive to 
differences in segmentation along the boundary of the 
lesion. Thus, if manual and automatic segmentations 
differed along the boundary, this can compromise the 
dice measure which is dependent on the degree of 
overlap. Furthermore, Dice coefficient can be sensitive 
to lesion size in that a few voxel difference in the loca-
tion of the boundary can substantially reduce the Dice 
for small lesions but not as much for large lesions. In 
contrast, ICC of volume is less sensitive to boundary 
effects. If automatic segmentation was more conserv-
ative at some boundaries and more liberal at other 
boundaries compared with manual segmentation, these 
effects would cancel out and there would still be high 
concordance between manual and automatic volumes. 
Indeed, this is the case, which is why the ICC values 
were higher than the Dice scores.
There are some limitations to our study. First, the ex-
pert manual volume segmentations for each patient were 
derived from a single rater, which limits our ability to as-
sess interrater variability of volume segmentation. Future 
studies could incorporate segmentations from multiple 
raters for segmentation. Second, our postoperative pa-
tient cohort contained imaging from only 54 patients from 
a single institution. Additional studies could utilize a larger, 
multi-institutional cohort as well as assess performance 
early after surgery versus later after surgery as well as in re-
sponsive versus progressive disease. Third, our approach 
utilized a single neural network architecture without com-
parison with other approaches. Future work could explore 
the clinical utility of other neural network architectures 
as well as ensembles of neural network models.32 
Furthermore, only patients with residual enhancing tumor 
of a certain size after surgery were enrolled in the clinical 
trials, which limits applicability to smaller tumors which 
may be harder to segment. Additionally, patient cohorts 
with 2D or 3D MR imaging were used in this study, as 3D 
MR imaging is not always available at all institutions. The 
utilization of only 3D MR imaging would further improve 
the reliability of bidirectional and volume measures.8 
Lastly, the confidence of the algorithm in its segmentations 
could be added to our pipeline to flag segmentations that 
require further verification from clinicians.33 This would 
allow for more reliable integration into clinical workflows. 
Overall, our study shows that automated measures of 
tumor burden are highly reproducible and can reflect 
changes in tumor burden during the course of treatment. 
These automated tools could potentially be integrated in 
routine clinical care and imaging analyses performed as 
part of clinical trials and significantly enhance our accuracy 
in assessing treatment response.
We developed an open-source, fully automatic pipe-
line for brain extraction, tumor segmentation, and RANO 
measurements and applied it to a large, multi-institutional 
preoperative and postoperative glioma patient cohort. 
We showed that automated volume and AutoRANO 
measurements are highly reproducible and are in agree-
ment with human experts in terms of change in tumor 
burden during the course of treatment. This tool may be 
helpful in clinical trials and clinical practice for expediting 
measurement of tumor burden in the evaluation of treat-
ment response, decreasing clinician burden associ-
ated with manual tumor segmentation and decreasing 
interobserver variability. Furthermore, our study serves as 
a proof of concept for automated tools in the clinic with po-
tential application to other tumor pathologies.
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Supplementary data are available at Neuro-Oncology 
online.
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